HK1207303A1 - Compositions and methods for inhibiting the activity of lar family phosphatases lar - Google Patents

Compositions and methods for inhibiting the activity of lar family phosphatases lar

Info

Publication number
HK1207303A1
HK1207303A1 HK15107985.5A HK15107985A HK1207303A1 HK 1207303 A1 HK1207303 A1 HK 1207303A1 HK 15107985 A HK15107985 A HK 15107985A HK 1207303 A1 HK1207303 A1 HK 1207303A1
Authority
HK
Hong Kong
Prior art keywords
lar
inhibiting
compositions
activity
methods
Prior art date
Application number
HK15107985.5A
Other languages
English (en)
Chinese (zh)
Inventor
Bradley T Lang
Jared M Cregg
Jerry Silver
Yi-Lan Wang
Original Assignee
Univ Case Western Reserve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Case Western Reserve filed Critical Univ Case Western Reserve
Publication of HK1207303A1 publication Critical patent/HK1207303A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
HK15107985.5A 2012-04-09 2015-08-18 Compositions and methods for inhibiting the activity of lar family phosphatases lar HK1207303A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261621623P 2012-04-09 2012-04-09
PCT/US2013/035831 WO2013155103A1 (en) 2012-04-09 2013-04-09 Compositions and methods for inhibiting the activity of lar family phosphatases

Publications (1)

Publication Number Publication Date
HK1207303A1 true HK1207303A1 (en) 2016-01-29

Family

ID=49328105

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107985.5A HK1207303A1 (en) 2012-04-09 2015-08-18 Compositions and methods for inhibiting the activity of lar family phosphatases lar

Country Status (8)

Country Link
US (1) US9937242B2 (xx)
EP (3) EP4285919A1 (xx)
JP (4) JP6268164B2 (xx)
AU (1) AU2013246034B2 (xx)
CA (2) CA2870155C (xx)
ES (1) ES2699658T3 (xx)
HK (1) HK1207303A1 (xx)
WO (1) WO2013155103A1 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2355728A (en) 1999-10-27 2001-05-02 Anson Medical Ltd Tubular medical implants and methods of manufacture
US7196710B1 (en) 2000-08-23 2007-03-27 Nintendo Co., Ltd. Method and apparatus for buffering graphics data in a graphics system
DK2495327T3 (da) 2006-03-03 2017-01-02 Promis Neurosciences Inc Fremgangsmåder og sammensætninger til at behandle og opdage sygdomme fremkaldt af fejlfoldet SOD1
US10786541B2 (en) 2012-04-09 2020-09-29 Case Western Reserve University Compositions and methods for treating heart disease and/or injury
US10206967B2 (en) 2012-04-09 2019-02-19 Case Western Reserve University Compositions and methods for treating heart disease and/or injury
ES2699658T3 (es) * 2012-04-09 2019-02-12 Univ Case Western Reserve Composiciones para su uso en el tratamiento de lesión neural inhibiendo la actividad de fosfatasas de la familia LAR
US10729777B2 (en) 2012-04-09 2020-08-04 Case Western Reserve University Compositions and methods for inhibiting the activity of LAR family phosphatases
WO2015134752A1 (en) * 2014-03-05 2015-09-11 Case Western Reserve University Compositions and methods for treating heart disease and/or injury
US10258672B2 (en) 2014-10-09 2019-04-16 Case Western Reserve University Compositions and methods of treating root avulsion injury
CA3063061A1 (en) * 2016-05-12 2017-11-16 Ohio State Innovation Foundation Peptides and methods for treating neurodegenerative disorders
KR20200045446A (ko) * 2017-06-05 2020-05-04 케이스 웨스턴 리저브 유니버시티 알츠하이머병의 치료를 위한 조성물 및 방법
WO2019014342A1 (en) * 2017-07-11 2019-01-17 Case Western Reserve University COMPOSITIONS AND METHODS FOR TREATING MYELIN DISEASES
CN113260373A (zh) * 2018-09-05 2021-08-13 卡斯西部储备大学 用于诱导神经可塑性的方法和组合物
KR102234449B1 (ko) * 2019-04-04 2021-03-30 재단법인대구경북과학기술원 불안 장애 예방 또는 치료를 위한 PTPσ　유전자 및 이를 이용한 스크리닝 방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4731058A (en) 1986-05-22 1988-03-15 Pharmacia Deltec, Inc. Drug delivery system
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
EP0557459B1 (en) 1990-11-13 1997-10-22 Immunex Corporation Bifunctional selectable fusion genes
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5368562A (en) 1993-07-30 1994-11-29 Pharmacia Deltec, Inc. Systems and methods for operating ambulatory medical devices such as drug delivery devices
JPH09504689A (ja) * 1993-10-01 1997-05-13 ニューヨーク ユニバーシティー 新規な受容体型ホスホチロシンホスファターゼσ
AU731044B2 (en) 1995-06-27 2001-03-22 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
CA2382789A1 (en) * 1999-08-27 2001-03-08 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
AU2001280767A1 (en) 2000-07-31 2002-02-13 Active Motif Peptide-mediated delivery of molecules into cells
WO2002083182A2 (en) * 2001-04-12 2002-10-24 Mcgill University The effect of receptor protein tyrosine phosphatase sigma (rptp-$g(s)) on neural axon regeneration and synapse modification
US7309485B2 (en) 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
ATE469913T1 (de) 2002-08-10 2010-06-15 Univ Yale Antagonisten des nogo-rezeptors
KR100814109B1 (ko) 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
US20090202544A1 (en) 2006-02-02 2009-08-13 The Trustees Of Columbia University In The City Of New York Methods of Treating Diseases by Targeting Silt3
KR100999043B1 (ko) * 2007-12-04 2010-12-09 한국생명공학연구원 융합 단백질을 사용하지 않는 인간 단백질 타이로신탈인산화 효소의 활성 도메인 대량 생산 방법
US8646989B2 (en) 2009-05-19 2014-02-11 Adc Telecommunications, Inc. Mechanical interface between a fiber optic cable and a fiber optic connector
US20120231014A1 (en) 2009-08-18 2012-09-13 Case Western Reserve University Neural Regeneration
US20130171163A1 (en) 2010-08-06 2013-07-04 Marschall Runge Inhibition of LAR Phosphatase to Enhance Therapeutic Angiogenesis
US9744188B2 (en) 2011-02-18 2017-08-29 President And Fellows Of Harvard College Methods of promoting neuronal outgrowth by gypican 2 that binds to receptor protein tyrosine phosphatase sigma
ES2699658T3 (es) * 2012-04-09 2019-02-12 Univ Case Western Reserve Composiciones para su uso en el tratamiento de lesión neural inhibiendo la actividad de fosfatasas de la familia LAR

Also Published As

Publication number Publication date
ES2699658T3 (es) 2019-02-12
EP2841086A1 (en) 2015-03-04
EP3446699B1 (en) 2023-06-07
JP6948250B2 (ja) 2021-10-13
JP2020186256A (ja) 2020-11-19
WO2013155103A1 (en) 2013-10-17
EP2841086B1 (en) 2018-09-26
JP2015516391A (ja) 2015-06-11
JP2023071909A (ja) 2023-05-23
US20150366949A1 (en) 2015-12-24
CA2870155A1 (en) 2013-10-17
CA2870155C (en) 2024-04-30
JP2018083823A (ja) 2018-05-31
AU2013246034B2 (en) 2017-12-07
US9937242B2 (en) 2018-04-10
EP2841086A4 (en) 2015-12-02
JP6268164B2 (ja) 2018-01-24
AU2013246034A1 (en) 2014-11-13
CA3233345A1 (en) 2013-10-17
EP3446699A1 (en) 2019-02-27
EP4285919A1 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
IL281295A (en) Preparations and methods for inhibiting expression of the ALAS1 gene
HK1207303A1 (en) Compositions and methods for inhibiting the activity of lar family phosphatases lar
IL266582A (en) Preparations and methods for the treatment of hemoglobin diseases
HK1213798A1 (zh) 治療性化合物和組合物
HK1207078A1 (en) Inhibition of enzymes
SG11201400668SA (en) Wnt compositions and therapeutic uses of such compositions
EP2858648A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING PIN1
IL238177A0 (en) Methods and preparations for the treatment of cancer
ZA201408056B (en) Compositions and methods for the treatment of mucositis
PL2598500T3 (pl) Kompozycje i sposoby hamowania szlaku JAK
HK1216250A1 (zh) '- '-羥基-二氫麥角胺化合物及組合物
EP2906041A4 (en) COMPOSITIONS AND METHODS OF USING INAPPETENCE COMPOUND
HK1202053A1 (en) Treatment of liver conditions
HK1201066A1 (en) Pyranopyridone inhibitors of tankyrase
EP2931280A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING CNKSR1
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
HK1254904B (zh) 用於改變xlhed表型的組合物和方法
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
EP2981334A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ACTIVITY
IL239623A0 (en) Methods and preparations for administering oxybutynin
HK1212998A1 (zh) 組合物及其使用方法
EP2917733A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS
IL233740A0 (en) Treatment of liver diseases
ZA201208374B (en) Protection of fasteners
EP2841164A4 (en) COMPOSITIONS AND USE PROCEDURES FOR THE SKIN